RhumbLine Advisers
STRO icon

RhumbLine Advisers’s Sutro Biopharma STRO Stock Holding History

RhumbLine Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,282
Closed -$79.9K – 4256
2025
Q1 		$79.9K Sell
12,282
-388
-3% -$6.11K ﹤0.01% 3460
2024
Q4 		$233K Buy
12,670
+732
+6% +$22.3K ﹤0.01% 3113
2024
Q3 		$413K Buy
11,938
+328
+3% +$12.9K ﹤0.01% 2836
2024
Q2 		$340K Buy
11,610
+2,194
+23% +$86.8K ﹤0.01% 2927
2024
Q1 		$532K Buy
9,416
+257
+3% +$11.4K ﹤0.01% 2636
2023
Q4 		$393K Sell
9,159
-31
-0.3% -$984 ﹤0.01% 2813
2023
Q3 		$319K Buy
9,190
+225
+3% +$9.8K ﹤0.01% 2898
2023
Q2 		$417K Buy
8,965
+495
+6% +$24.6K ﹤0.01% 2808
2023
Q1 		$391K Buy
8,470
+693
+9% +$44K ﹤0.01% 2523
2022
Q4 		$628K Buy
7,777
+679
+10% +$47.2K ﹤0.01% 2358
2022
Q3 		$394K Buy
7,098
+822
+13% +$48.7K ﹤0.01% 2605
2022
Q2 		$327K Buy
6,276
+758
+14% +$42.3K ﹤0.01% 2715
2022
Q1 		$454K Sell
5,518
-79
-1% -$7.52K ﹤0.01% 2467
2021
Q4 		$833K Buy
5,597
+73
+1% +$13.1K ﹤0.01% 2280
2021
Q3 		$1.04M Buy
5,524
+203
+4% +$38.6K ﹤0.01% 2213
2021
Q2 		$989K Buy
5,321
+2,396
+82% +$469K ﹤0.01% 2254
2021
Q1 		$666K Buy
2,925
+154
+6% +$36.5K ﹤0.01% 2362
2020
Q4 		$602K Buy
2,771
+720
+35% +$119K ﹤0.01% 2363
2020
Q3 		$206K Buy
2,051
+174
+9% +$16.4K ﹤0.01% 2673
2020
Q2 		$146K Buy
1,877
+497
+36% +$47.7K ﹤0.01% 2865
2020
Q1 		$141K Hold
1,380
– – ﹤0.01% 2696
2019
Q4 		$152K Buy
1,380
+22
+2% +$2.27K ﹤0.01% 2812
2019
Q3 		$123K Buy
1,358
+116
+9% +$11.7K ﹤0.01% 2854
2019
Q2 		$141K Buy
+1,242
New +$137K ﹤0.01% 2869

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

RhumbLine Advisers's STRO Position: Q2 2025 in Review

RhumbLine Advisers sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 12,282 shares — an estimated $79.9K sold.

RhumbLine Advisers first reported a position in STRO in Q2 2019 and held it in 24 quarters. The position peaked at $1.04M in Q3 2021. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • RhumbLine Advisers reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 12,282 Sutro Biopharma shares in Q2 2025, an estimated $79.9K.
  • RhumbLine Advisers first reported a position in Sutro Biopharma in Q2 2019 and held it in 24 quarters.
  • RhumbLine Advisers's Sutro Biopharma position peaked at $1.04M in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.